| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Sanara MedTech Inc.$23.88
-0.35 (-1.44%)
Market Cap
212.33 M
EPS
-3.89
P/E Ratio
-
Value Trade
1.04 M
SEC Financials
Q1 2026Dilution Risk
Revenue
27.80 M
R&D Expenses
759.59 K
Operating CF
-2.47 M
Total Assets
69.28 M
Total Liabilities
62.26 M
Equity
7.03 M
D/E Ratio
12,345
7.37 %
Week
16.78 %
1 Month
16.2 %
3 Month
21.56 %
6 Month
-14.18 %
5 Year
-81.46 %
All Time
Cash Data
Cash Position
27.76 M
Monthly Burn
822.00 K
Runway
32.1 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
67.94 K
52 Week Range
16.05 - 35.95
% held by Insiders
47.06 %
% held by Institutions
16.36 %
Enterprise Value
247.09 M
Total Shares
9.17 M
Short %
6.05 %
Float Shares
4.80 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SMTI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SMTI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SMTI▲ +13.4%on this news
Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)
Sanara MedTech Inc. reported a 19% increase in net revenue for Q1 2026, reaching $27.8 million, driven by strong sales in soft tissue repair products. The company achieved net profitability of $0.04 per diluted share, despite a rise in operating expenses. Looking ahead, Sanara maintains its full-year revenue growth guidance of 13% to 17%.
Read more →SMTI▲ +5.2%on this news· ran to +18% by day 3
Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026
Sanara MedTech Inc. will report its first quarter 2026 financial results on May 12, 2026, before the U.S. markets open. A conference call will be held at 8:00 a.m. ET to discuss the results and include a Q&A session. The company focuses on innovative surgical solutions to enhance clinical outcomes and reduce costs.
Read more →SMTI▲ +6.5%on this news· ran to +20% by day 3shared move
Sanara MedTech, Inc. Investigated by the Portnoy Law Firm
Sanara MedTech, Inc. is facing an investigation initiated by the Portnoy Law Firm over potential securities fraud related to the company's discontinuation of its Tissue Health Plus (THP) program. Following this announcement and the subsequent release of financial results, which reported a net loss from discontinued operations of $31.2 million, the company's stock plummeted by 24.7%. The law firm invites affected investors to participate in a class action to seek recovery for their losses. Concerns about corporate governance and financial management are front and center in this developing situation.
Read more →SMTIQ&A – Prevention Strategies for Surgical Site Infections: Perspectives from a Plastic Surgeon and General Surgeon Webinar
The article discusses a webinar featuring Dr. Prodromos Ververeli, Dr. Asaf Yalif, and Dr. Rory Snepar, focusing on prevention strategies for surgical site infections. The presenters share their expertise and perspectives on the topic, emphasizing the importance of addressing these infections in surgical settings. The content serves as an informational resource for medical professionals.
Read more →SMTIPlastic Surgery and General Surgery Case Discussion
The article discusses a case presentation in plastic and general surgery by Dr. Prodromos Ververeli, Dr. Asaf Yalif, and Dr. Rory Snepar. It emphasizes the importance of seeking professional medical advice and clarifies that the content is for informational purposes only. The article also includes disclaimers regarding the use of the content and its limitations.
Read more →SMTIEvidence and Rationale on Infection Prevention Protocol Selections in Plastic Surgery and General Surgery
The article discusses infection prevention protocols in plastic and general surgery, presented by Dr. Prodromos Ververeli, Dr. Asaf Yalif, and Dr. Rory Snepar. It emphasizes the importance of adhering to professional medical advice and manufacturer instructions. The content is intended for informational purposes only and does not substitute for professional consultation.
Read more →SMTISurgical Site Infection Prevention Protocol in Plastic Surgery and General Surgery
The article discusses a presentation on surgical site infection prevention protocols in plastic and general surgery by Dr. Prodromos Ververeli, Dr. Asaf Yalif, and Dr. Rory Snepar. It emphasizes the importance of following professional medical advice and the limitations of the website's content. The article serves as an informational resource without substituting for medical guidance.
Read more →SMTISurgical Site Infections in Plastic Surgery and General Surgery: Epidemiology and Challenges
The article discusses the epidemiology and challenges of surgical site infections in plastic and general surgery. It highlights the importance of understanding these infections to improve patient outcomes. The content is presented by Dr. Prodromos Ververeli, Dr. Asaf Yalif, and Dr. Rory Snepar, emphasizing the need for professional medical advice.
Read more →SMTISanara MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial Results; Reaffirmed Full Year 2026 Financial Guidance
Sanara MedTech Inc. reported a 19% increase in net revenue for 2025, reaching $103.1 million. The company also achieved an adjusted EBITDA of $17.0 million, up from $9.1 million in 2024. Despite a net loss from continuing operations, Sanara reaffirmed its financial guidance for 2026, projecting revenue growth of 13% to 17%. The company continues to focus on expanding its surgical product offerings.
Read more →SMTISanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX Surgical Powder in the Management of Spine Surgery Wounds
Sanara MedTech Inc. announced the publication of a peer-reviewed study in the Journal of Medical Economics, highlighting the benefits of CellerateRX Surgical Powder as an adjunct treatment for high-risk spinal surgery patients. The study showed that using CellerateRX resulted in substantial cost savings and improvements in health outcomes compared to standard care alone. Specifically, it demonstrated a cost saving of $3,852 per patient and improved quality-adjusted life years (QALYs), supporting CellerateRX as a valuable addition to surgical wound management. Sanara plans to raise awareness of this study in the marketplace to promote its clinical effectiveness.
Read more →SMTISanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
Sanara MedTech Inc. will report its fourth quarter and full year 2025 financial results on March 24, 2026. A conference call is scheduled for the same day to discuss the results and include a Q&A session. The company emphasizes its commitment to developing transformative technologies in the surgical market.
Read more →SMTISanara MedTech Inc. to Participate in the TD Cowen 46th Annual Health Care Conference on March 3rd
Sanara MedTech Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 3, 2026. The company will present its innovative surgical technologies aimed at improving clinical outcomes and reducing costs. Presentation materials will be available on their investor relations website, along with a live audio webcast.
Read more →SMTIQ&A Session on Incorporating Hydrolyzed Collagen Surgical Powder into Clinical Practice
The article discusses an upcoming Q&A session featuring experts Prodromos Ververeli, MD, Merritt Kinon, MD, and Vivek Mohan, MD, focused on the incorporation of hydrolyzed collagen surgical powder into clinical practice. This session is intended to provide insights and enhance understanding of the product's application in surgery. Attendees are encouraged to seek professional medical advice regarding the use of such products.
Read more →SMTIIntegrating a Surgical Wound Complication Management Protocol into Practice: Spine Case Review
The article discusses a presentation by Dr. Merritt Kinon and Dr. Vivek Mohan on integrating a surgical wound complication management protocol into practice, specifically focusing on spine cases. It emphasizes the importance of professional medical advice and cautions against using the content as a substitute for medical guidance. The article is part of a broader discussion on surgical practices and related medical topics.
Read more →SMTICellerateRX® Surgical Powder Cost-Effectiveness Analysis in Spine Surgery
The article discusses a cost-effectiveness analysis of CellerateRX® Surgical Powder in spine surgery, presented by Dr. Vivek Mohan. The analysis aims to evaluate the economic benefits of using this product in surgical settings. The findings could potentially influence future practices in spine surgery.
Read more →SMTIClinical Benefits of Hydrolyzed Collagen in Spine Surgery
The article discusses the clinical benefits of hydrolyzed collagen in spine surgery, presented by Dr. Vivek Mohan. It emphasizes that the content is for informational purposes and should not replace professional medical advice. The article also includes disclaimers regarding the use of the content and encourages consultation with qualified health providers.
Read more →SMTISurgical Site Infections (SSI) in Spine Surgery: Incidence, Impact & Challenges
The article discusses the incidence, impact, and challenges associated with Surgical Site Infections (SSI) in spine surgery. It highlights the importance of understanding these infections to improve patient outcomes. The content is presented by Dr. Merritt Kinon and emphasizes the need for professional medical advice regarding treatment and product usage.
Read more →SMTIA Novel Approach to Vulvectomy Care: The Role of Hydrolyzed Collagen Surgical Powder
The article discusses a presentation by Dr. Nefertiti duPont on a novel approach to vulvectomy care using hydrolyzed collagen surgical powder. It emphasizes the importance of consulting healthcare professionals for medical advice and product usage. The content serves as informational material and does not replace professional guidance.
Read more →SMTIAdjuvant Hydrolyzed Collagen Powder in High-risk Patients With Large Soft Tissue Defects Undergoing Orthoplastic Limb Preservation Surgery
The article discusses a presentation by Dr. Christopher Bibbo on the use of adjuvant hydrolyzed collagen powder in high-risk patients undergoing orthoplastic limb preservation surgery. The treatment aims to address large soft tissue defects, potentially enhancing surgical outcomes. The content emphasizes the importance of consulting healthcare professionals regarding treatment options.
Read more →SMTIBone Biology and Physiology: Dynamic Interplay of Strength and Function
The article discusses the dynamic nature of bone biology, emphasizing its continuous remodeling process involving osteoclasts and osteoblasts. It highlights the hierarchical structure of bone from nanoscale to macroscale, detailing how this architecture supports mechanical strength and functionality. Additionally, it covers the mechanisms of fracture healing and the importance of adapting clinical approaches for effective treatment.
Read more →SMTIOTA 2025 Part 3 of 3: Open Fracture Case Review: Protocol Integration for Infection Prevention
The article discusses a presentation by Dr. Thomas Hand on the integration of protocols for infection prevention in open fracture case reviews. It emphasizes the importance of professional medical advice and cautions against using the content as a substitute for medical guidance. The information is primarily for informational purposes.
Read more →SMTIOTA 2025 Part 1 of 3: Current Challenges in Fracture-Related Infection Management
The article discusses the current challenges in managing fracture-related infections, presented by Dr. Thomas Hand. It emphasizes the importance of professional medical advice and cautions against relying solely on the website's content for medical decisions. The content is intended for informational purposes and should not replace professional guidance.
Read more →SMTISanara MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial Guidance
Sanara MedTech Inc. reported preliminary financial results for Q4 and full year 2025, showing a 19% increase in net revenue. The company also provided guidance for 2026, expecting revenue growth of 13% to 17%, driven by its soft tissue products. A new contract with Vizient enhances market access for its offerings.
Read more →SMTIOTA 2025 Part 2 of 3: Fracture Related Infections and the Role of Intraoperative Irrigation Solutions
The article discusses a presentation by Dr. Ravi Karia on fracture-related infections and the role of intraoperative irrigation solutions. It emphasizes the importance of seeking professional medical advice and adhering to manufacturer instructions. The content is intended for informational purposes only and does not substitute for professional guidance.
Read more →SMTIAAHKS 2025 Part 4 of 4: Joint Replacement Case Reviews – Using an Advanced Intraoperative Irrigation Solution
The article discusses a presentation by Dr. Frank Buttacavoli at the AAHKS 2025 conference, focusing on joint replacement case reviews and the use of an advanced intraoperative irrigation solution. It emphasizes the importance of professional medical advice and cautions against substituting the content for medical guidance. The article also includes notices about related posts and company information.
Read more →SMTIAAHKS 2025 Part 3 of 4: Intraoperative Wound Irrigation: Clinical Practice Trends and Consensus in Joint Replacement Surgery
The article discusses the upcoming presentation by Dr. Jonathan Danoff at AAHKS 2025, focusing on intraoperative wound irrigation trends and consensus in joint replacement surgery. It emphasizes the importance of seeking professional medical advice and adhering to manufacturer instructions. The content serves as an informational resource rather than a substitute for medical guidance.
Read more →SMTIAAHKS 2025 Part 2 of 4: Advanced Irrigation Solutions in Orthopedics – Evidence in Focus
The article discusses a presentation by Dr. Alberto Carli at the AAHKS 2025 conference, focusing on advanced irrigation solutions in orthopedics. It emphasizes the importance of professional medical advice and cautions against using the website's content as a substitute for medical guidance. The content is intended for informational purposes only.
Read more →SMTIAAHKS 2025 Part 1 of 4: What is the Current Challenge in Periprosthetic Joint Infections?
The article discusses a presentation by Dr. David Rodriguez at the AAHKS 2025 conference, focusing on the challenges associated with periprosthetic joint infections. It emphasizes the importance of professional medical advice and the need for proper diagnosis and treatment. The content serves as an informational resource rather than a substitute for medical guidance.
Read more →SMTISanara MedTech Inc. Receives Innovative Technology Contract from Vizient for BIASURGE Advanced Surgical Solution
Sanara MedTech Inc. has been awarded an Innovative Technology contract by Vizient Inc. for its BIASURGE Advanced Surgical Solution. This recognition is based on the product's recommendation by hospital experts, highlighting its potential to enhance surgical outcomes and patient safety. The contract, effective January 1, 2026, allows access to BIASURGE at negotiated pricing for Vizient's extensive healthcare network. The BIASURGE solution offers a no-rinse irrigation option, enhancing the efficiency of surgical cleansing while providing antimicrobial protection.
Read more →SMTICemented vs. Cementless Fixation Joint Replacement Surgery: A Review for You
The article reviews cemented and cementless fixation methods in joint replacement surgery, highlighting their benefits and suitable patient profiles. Cemented fixation provides immediate stability and is ideal for older patients or those with osteoporosis, while cementless fixation promotes bone integration and is suited for younger, active individuals. The choice of fixation method should be personalized based on various factors.
Read more →SMTIClearing the Way: Understanding Irrigation Solutions in Surgery
Irrigation solutions are crucial sterile fluids used in surgeries to cleanse tissues and reduce infection risks. Common types include normal saline, sterile water, and antimicrobial solutions, each serving specific purposes. While they enhance surgical outcomes, improper use can lead to complications such as tissue damage and antibiotic resistance. Surgeons must carefully select the appropriate solutions based on patient needs.
Read more →SMTISanara MedTech Inc. and Biomimetic Innovations Provide Update on OsStic™
Sanara MedTech Inc. and Biomimetic Innovations have announced progress on their OsStic™ bio-adhesive, set for U.S. market launch in Q1 2027. The FDA granted OsStic Breakthrough Device Designation, recognizing its potential for treating peri-articular fractures. The product boasts superior bonding capabilities and is expected to address critical needs in orthopedic surgery.
Read more →SMTI▼ -8.8%on this news
Sanara MedTech to Participate in the Piper Sandler 37th Annual Healthcare Conference on December 3rd
Sanara MedTech Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025. Management is scheduled to present on December 3 at 9:30 a.m. ET. The presentation materials will be available on the company's investor relations website, along with a live audio webcast.
Read more →SMTI▼ -24.7%on this news
Sanara MedTech Inc. Reports Third Quarter 2025 Financial Results (Unaudited)
Sanara MedTech Inc. reported a 22% increase in net revenue for Q3 2025, reaching $26.3 million, driven by strong sales of surgical soft tissue products. The company also noted improvements in profitability, with adjusted EBITDA rising to $4.9 million. However, it faced a significant net loss of $30.4 million due to discontinued operations and an asset impairment charge. The company has ceased operations of its THP segment to focus on its core surgical business.
Read more →SMTI▼ -24.7%on this newsshared move
Sanara MedTech Inc. Announces Strategic Realignment to Focus on Surgical Business
Sanara MedTech Inc. has completed an evaluation of its Tissue Health Plus segment, resulting in a strategic realignment to focus on its surgical business. The company will discontinue THP operations to improve efficiency and reallocate resources. This decision is based on the surgical business's strong revenue growth and potential for sustainable value creation.
Read more →SMTIIn Vitro Compatibility Assessment of BIASURGE® Advanced Surgical Solution with Implantable Materials and Closure Technologies
The article discusses the in vitro compatibility assessment of BIASURGE® Advanced Surgical Solution with various implantable materials and closure technologies. It emphasizes the importance of this assessment for ensuring safety and effectiveness in surgical applications. The content is primarily informational and does not provide specific results or conclusions.
Read more →SMTIIn Vitro Comparison of the Rapid Bactericidal Efficacy of Commercially Available Surgical Solutions
The article discusses an in vitro comparison of the bactericidal efficacy of various commercially available surgical solutions. It emphasizes that the content is for informational purposes only and should not replace professional medical advice. The authors include Prodromos Ververeli, MD, Asaf Yalif, MD, and Rory Snepar, DO.
Read more →SMTISanara MedTech to Report Third Quarter 2025 Financial Results on November 12, 2025
Sanara MedTech Inc. announced plans to report its third quarter 2025 financial results on November 12, 2025, before the U.S. markets open. The company will hold a conference call and webcast on the same day to discuss the outcomes and answer questions. Sanara MedTech specializes in medical technologies aimed at improving clinical results and lowering healthcare costs in surgical and wound care markets.
Read more →SMTIInsights from the Operating Room: National Survey Results of Orthopedic Surgeons’ Perspective on Intraoperative Wound Irrigation
A national survey of 112 orthopedic surgeons reveals that over 99% use intraoperative wound irrigation (IOWI) during procedures, primarily at closure. While saline remains the dominant solution, there is a cautious shift towards antiseptics, particularly in high-risk cases. The survey highlights the need for standardized protocols and better education on irrigation practices to reduce surgical site infections (SSIs).
Read more →SMTIIn Vitro Prevention and Eradication of Microbial Biofilms on Implantable Materials with BIASURGE® Advanced Surgical Solution
The article discusses the BIASURGE® Advanced Surgical Solution, which focuses on the in vitro prevention and eradication of microbial biofilms on implantable materials. It emphasizes the importance of consulting healthcare professionals regarding medical conditions and product usage. The content serves as informational and does not replace professional medical advice.
Read more →SMTIIn Vitro Evaluation of Microbicidal Efficacy of BIASURGE® Advanced Surgical Solution
The article discusses the in vitro evaluation of the microbicidal efficacy of BIASURGE® Advanced Surgical Solution. It emphasizes the importance of consulting healthcare professionals for medical advice and product usage. The content serves as informational and does not substitute for professional guidance or manufacturer instructions.
Read more →SMTIThe Application of Hydrolyzed Collagen Powder for Prevention of Incisional Wound Complications in Morbidly Obese Patients Undergoing Direct Anterior Approach to Total Hip Arthroplasty
Dr. Frank Buttacavoli from the University of Texas Health presented findings on the use of hydrolyzed collagen powder to prevent incisional wound complications in morbidly obese patients undergoing total hip arthroplasty. The study highlights the potential benefits of collagen in enhancing surgical recovery. It emphasizes the importance of addressing complications in this patient demographic.
Read more →SMTIComparison of Wound Irrigation Solutions Using an Ex vivo Human Bone Organ Culture
The article discusses a presentation by Dr. David Rodriguez from the University of Texas Health regarding the antibacterial effectiveness of various wound irrigation solutions using an ex vivo human bone organ culture model. It emphasizes the importance of professional medical advice and the limitations of the content provided. The article also includes a notice about the website's content not being a substitute for medical guidance.
Read more →SMTISanara MedTech Inc. Announces Chief Executive Officer Transition
Sanara MedTech Inc. has announced the appointment of Seth Yon as President and CEO, effective September 15, 2025. He succeeds Ron Nixon, who will continue as Executive Chairman. The Board believes Yon's leadership will drive the company's growth and success in the medical technology sector. Yon has been with Sanara since 2018 and has played a key role in its commercial strategy.
Read more →SMTIEx vivo Human Bone Organ Culture Evaluation of Surgical Irrigation Solutions: Antimicrobial Efficacy and Cytocompatibility
The study assesses seven irrigation solutions for surgical use, focusing on their antimicrobial effectiveness and safety for human tissue. Solutions evaluated include PHMB, PVP-I, CHG, and BZK. The research aims to identify the most effective options for surgical irrigation, ensuring both robust antibacterial activity and tissue compatibility.
Read more →SMTISanara MedTech Inc. to Present at the Cantor Global Healthcare Conference on September 3, 2025
Sanara MedTech Inc. announced its participation in the Cantor Global Healthcare Conference from September 2-5, 2025. The management will present during a fireside chat on September 3 at 2:45 p.m. ET. Presentation materials will be available on the company's investor relations website, along with a live audio webcast.
Read more →SMTI▲ +16.2%on this news
Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited) Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strateg
Sanara MedTech Inc. reported a 28% year-over-year increase in net revenue for Q2 2025, totaling $25.8 million. The company also improved its adjusted EBITDA to $2.7 million compared to $0.6 million in the same quarter last year. However, the net loss for the first half of 2025 increased slightly to $5.5 million. Additionally, the company announced it is evaluating strategic alternatives for its Tissue Health Plus subsidiary due to ongoing financial challenges.
Read more →SMTIA Silent Architect of Post-Surgical Healing: The Extracellular Matrix
The article discusses the vital role of the extracellular matrix (ECM) in post-surgical healing. It highlights how the ECM facilitates tissue repair through dynamic interactions with cells, influencing processes like inflammation, proliferation, and remodeling. The article also addresses potential complications arising from disrupted ECM dynamics and emphasizes modern therapeutic strategies aimed at supporting ECM integrity for improved healing outcomes.
Read more →SMTI▼ -5.7%on this news
Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025
Sanara MedTech Inc. will announce its financial results for the second quarter of 2025 on August 13, 2025, before U.S. markets open. A conference call and webcast will be held at 8:00 a.m. Eastern Time to discuss the results and allow for a Q&A session. The company's focus is on advancing medical technologies aimed at improving clinical outcomes in various markets, including surgical and chronic wound care. Future updates will be available through their Investor Relations website.
Read more →SMTI▼ -5.7%on this newsshared move
Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program
Sanara MedTech Inc. has launched a pilot program through its subsidiary, Tissue Health Plus, aimed at enhancing wound care management. This program will utilize THP's technology platform to standardize treatment and improve patient outcomes across six states. The initiative represents a significant step towards value-based care in chronic wound management.
Read more →SMTI▼ -10.8%on this news
Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited) Q1 Net Revenue Increased 26% Year-Over-Year
Sanara MedTech Inc. reported a 26% increase in net revenue for the first quarter of 2025, totaling $23.4 million. However, the company also experienced a rise in net losses, which reached $3.5 million compared to $1.8 million in the same period last year. Adjusted EBITDA improved to $0.7 million, and the company is expanding its product offerings through partnerships and an enhanced leadership team. Despite the positive revenue growth, operational expenses increased significantly, putting pressure on profitability.
Read more →SMTISanara MedTech to Report First Quarter 2025 Financial Results on May 14, 2025
Sanara MedTech Inc. announced the scheduling of its first quarter 2025 financial results to be reported on May 14, 2025, prior to U.S. market opening. The company will also host a conference call at 8:00 a.m. Eastern Time that same day to discuss the financial outcomes and field questions. Sanara continues to develop innovative healthcare solutions aimed at improving clinical outcomes and reducing costs, particularly in the surgical and wound care sectors.
Read more →SMTISanara MedTech to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
Sanara MedTech Inc. (Ticker: SMTI) is set to present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025. The event will take place at the Paris Hotel & Casino in Las Vegas, where management intends to highlight the company's efforts in developing transformative medical technologies. The presentation materials will be made available online, and the presentation will also be accessible via a live audio webcast. Sanara focuses on improving clinical outcomes in surgical, chronic wound, and skincare markets.
Read more →SMTI▼ -12.6%on this news
Sanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited) Q4 Net Revenue Increased 49% Year-Over-Year; 2024 Net Revenue Increased 33% Year-Over-Year
Sanara MedTech Inc. reported its fourth quarter 2024 financial results, showing a significant 49% increase in net revenue compared to the previous year. The total net revenue for 2024 reached $86.7 million, reflecting a 33% year-over-year growth. Despite this growth, the company posted a net loss of $9.9 million for the year, worsening from a $4.4 million loss in 2023, primarily due to elevated expenses in selling, general, and administrative costs. The company is pursuing potential financial partnerships to support its new Tissue Health Plus segment, which aims to launch its pilot program in 2025.
Read more →SMTISanara MedTech to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
Sanara MedTech Inc. (Nasdaq: SMTI) announced that it will report its fourth quarter and full year 2024 financial results on March 25, 2025, before the U.S. markets open. This will be followed by a conference call at 8:00 a.m. Eastern Time, where the company will discuss the results and engage with investors. Sanara MedTech focuses on transformative technologies in healthcare, particularly in surgical and wound care markets.
Read more →SMTISanara MedTech Inc. Expands Executive Leadership Team with New Appointments Elizabeth Taylor Appointed Chief Financial Officer; Michael McNeil Appointed Chief Accounting Officer and Chief Administrative Officer
Sanara MedTech Inc. has expanded its executive leadership by appointing Elizabeth Taylor as Chief Financial Officer and Michael McNeil as Chief Accounting Officer and Chief Administrative Officer. Taylor, who has over 25 years of financial experience including previous roles in medical device companies and hedge funds, is expected to enhance the company's financial strategies. McNeil will continue to lead financial reporting and accounting as part of his new role. These appointments are part of the company's strategy to grow and capitalize on opportunities in the surgical, chronic wound, and skincare markets.
Read more →SMTISanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd OsStic and related technologies represent differentiated solutions that address an e
Sanara MedTech Inc. has entered into an exclusive licensing and distribution agreement with Biomimetic Innovations Ltd for the OsStic technology, aimed at enhancing fracture repair. This arrangement includes a minority investment of up to $8 million by Sanara, which seeks to leverage its commercial infrastructure to market OsStic in the U.S. The FDA has granted OsStic Breakthrough Device Designation, indicating its innovative potential for treating periarticular fractures. Sanara plans to introduce this technology to the U.S. market in early 2027, complementing its existing product offerings.
Read more →SMTISanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024 Fourth Quarter Net Revenue Expected to Increase 45% to 48% Year-Over-Year; Full Year Net Revenue Expected to Increase 32
Sanara MedTech Inc. has reported unaudited preliminary results for the fourth quarter and full year of 2024, indicating a significant expected increase in net revenue. The company anticipates quarterly revenue growth between 45% to 48% year-over-year, further complemented by impressive sales of its BIASURGE product. Despite reliance on temporary market conditions due to shortages in IV fluids, Sanara confirms strong operational progress, including multiple patent applications. Final audit results may lead to adjustments in these preliminary estimates.
Read more →SMTIUnderstanding Hip Fractures: Diagnosis and Treatment
Hip fractures are prevalent among older adults and require urgent medical attention. Prompt surgical intervention can significantly improve recovery outcomes and reduce complications. Various types of hip fractures exist, each necessitating specific treatment approaches, including internal fixation and joint replacement. Rehabilitation plays a crucial role in recovery, helping patients regain mobility and quality of life.
Read more →SMTISanara MedTech to Present at the Piper Sandler 36th Annual Healthcare Conference on December 4th
Sanara MedTech Inc. announced that its Chairman and CEO, Ron Nixon, will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024. The presentation aims to provide insights to investors and will be accessible through a live audio webcast. Sanara MedTech focuses on developing transformative technologies aimed at improving clinical outcomes in surgical, chronic wound, and skincare markets, with a portfolio of innovative products and a commitment to future development.
Read more →SMTISanara MedTech Inc. Reports Third Quarter 2024 Results FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. reported strong third quarter results for 2024, achieving a record net revenue of $21.7 million, marking the twelfth consecutive quarter of revenue growth. The company attributed this success to increased sales of its tissue repair products and an expansion in market penetration. However, it also faced a higher net loss of $2.9 million due to escalating SG&A costs and increased interest expenses. Looking ahead, Sanara is focused on executing its growth strategy to deliver value to stakeholders.
Read more →SMTISanara MedTech Inc. Announces Third Quarter Earnings Release and Conference Call Dates
Sanara MedTech Inc., a Fort Worth-based medical technology company, announced the release of its earnings results for the third quarter ending September 30, 2024. The earnings will be released on November 12, 2024, and followed by a conference call on November 13, 2024. The company focuses on developing technologies that enhance clinical outcomes in the surgical, chronic wound, and skincare markets. The earnings release and subsequent teleconference reflect the company's commitment to transparency with its investors.
Read more →SMTISanara MedTech Inc. Announces Changes to Its Board of Directors FORT WORTH, TX / ACCESSWIRE /
Sanara MedTech Inc. has announced changes to its Board of Directors, with Mr. James Stuckert resigning after a long tenure. Keith Myers has been appointed as the new director, recognized for his leadership at LHC Group. Sanara's Executive Chairman, Nixon, praised Stuckert's leadership and highlighted Myers' valuable experience for the company's growth. The changes reflect Sanara's commitment to evolving in the medical technology space.
Read more →SMTIIn Vitro and In Vivo Characterization of BiFORM® Bioactive Moldable Matrix
The study evaluated the BiFORM® Bioactive Moldable Matrix in a rabbit spinal fusion model, comparing its effectiveness to Vitoss® BA and autograft. Results indicated that BiFORM® achieved approximately double the fusion rates of Vitoss® at 14 weeks. The matrix also demonstrated substantial bioactivity, inducing significant calcium phosphate layer formation in vitro. Overall, BiFORM® showed promising results for spinal fusion applications.
Read more →SMTISanara MedTech Inc. and InfuSystem Holdings, Inc. Announce Exclusive United States Distribution Agreement with, and Minority Investment in, ChemoMouthpiece, LLC FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. and InfuSystem Holdings, Inc. have entered into an exclusive distribution agreement with a minority investment in ChemoMouthpiece, LLC to market an oral cryotherapy device aimed at relieving oral mucositis in oncology patients. The device, which has received FDA 510(k) clearance, is expected to address a significant need in cancer care by improving patient comfort during chemotherapy. Furthermore, the American Medical Association has issued a CPT code for the device, potentially facilitating reimbursement for its use. This collaboration leverages the strengths of both Sanara and InfuSystem to enhance patient outcomes in oncology clinics across the United States.
Read more →SMTIBiofilm in Acute Surgical Wounds: Advances in Prevention and Treatment
The article discusses the role of biofilms in acute surgical wounds and their contribution to surgical site infections (SSIs). It highlights the challenges posed by biofilms, including their resistance to antibiotics and the risks of re-colonization on implants. Advances in prevention techniques, such as improved irrigation solutions and biofilm-eradicating tools, are emphasized as critical for reducing infection rates and improving surgical outcomes.
Read more →SMTISanara MedTech Inc. Announces Second Quarter 2024 Results FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. reported its financial results for the second quarter of 2024, achieving record revenue of $20.2 million, marking a 28% increase from the same quarter in 2023. This growth was driven by successful sales of their soft tissue repair products and expansion into new territories, leading to product availability in over 800 facilities. Despite these accomplishments, the company reported a higher net loss of $3.5 million due to increased costs in sales and marketing, acquisitions, and amortization expenses. The company has also undertaken measures to strengthen its management team as part of its growth strategy.
Read more →SMTISanara MedTech Inc. Announces Second Quarter Earnings Release and Conference Call Dates
Sanara MedTech Inc. has announced the details for its second quarter earnings release, which will take place on August 12, 2024. This will be followed by a conference call on August 13, 2024, to discuss the earnings results. The call will provide an opportunity for investor engagement and insights into the company's financial performance. Sanara continues to focus on developing transformative medical technologies to enhance clinical outcomes and reduce costs in healthcare.
Read more →SMTIComparison of the Rapid Bactericidal Efficacy of Commercially Available Surgical Solutions
The article presents a comparative study assessing the rapid bactericidal efficacy of nine commercially available irrigation solutions. Using a short contact time of 60 seconds, the study tested solutions against two bacterial species: MRSA and Pseudomonas aeruginosa. The solutions included various antimicrobial technologies and preservatives, highlighting their potential clinical applications.
Read more →SMTICompatibility Assessment of BIASURGE® Advanced Surgical Solution with Implantable Materials and Closure Technologies
The study evaluates the compatibility of BIASURGE with blood clotting and various surgical materials, including bone cements and adhesives. It also assesses the product's effects on common prosthetic metals, finding no corrosive or oxidative properties. These findings suggest BIASURGE could enhance surgical outcomes.
Read more →SMTI▼ -6.8%on this news
Sanara MedTech Inc. Announces First Quarter 2024 Results FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. reported its first quarter 2024 results, showcasing a 19% increase in net revenue to $18.5 million compared to the prior year. Despite achieving its tenth consecutive record revenue quarter and making significant operational advancements, the company experienced a net loss of $1.8 million, largely due to increased selling, general, and administrative costs. The resignation of the former CEO raises questions about leadership stability as the company aims to strengthen its executive team. Continued focus on expanding market penetration and improving performance is highlighted as key to ongoing success.
Read more →SMTISanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call Dates
Sanara MedTech Inc. has announced the dates for its first quarter earnings release and subsequent conference call. The earnings report will be issued on May 13, 2024, followed by a conference call on May 14, 2024, at 9:00 a.m. Eastern Time. This announcement reflects the company's ongoing efforts to engage with investors and provide updates on its clinical and financial performance. Sanara MedTech focuses on developing innovative medical technologies aimed at improving patient outcomes and reducing costs in healthcare.
Read more →SMTI▲ +7.6%on this news
Sanara MedTech Inc. Announces $55 Million Debt Facility FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. has announced a $55 million debt facility to support its growth initiatives for 2024 and 2025. The funding, secured through a non-dilutive term loan agreement with CRG Servicing LLC, allows the company to retire existing debt and has the potential for additional capital through future draws. The CEO highlighted that this partnership aligns with their growth strategy and will facilitate new opportunities for acquisitions and investments.
Read more →SMTIPrevention of microbial biofilms on implantable materials in vitro with BIASURGE™ Advanced Surgical Solution
The study evaluates the effectiveness of BIASURGE™ Advanced Surgical Solution in preventing microbial colonization and eradicating bacteria from various implantable materials. The research involved detailed in vitro studies that assessed both prevention and eradication methodologies. Findings indicate promising results for improving surgical outcomes.
Read more →SMTISanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. has announced the appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer. Both Waldrop and Palmer bring extensive experience in the medical device and healthcare sectors, which the company believes will enhance its operations and strategic initiatives. Waldrop's role will begin on April 15, 2024, while Palmer started on April 1, 2024. This expansion in leadership is aimed at improving clinical outcomes through innovative medical solutions and expanding Sanara's market presence.
Read more →SMTISanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. reported its fourth quarter and full year results for 2023, showcasing robust growth with net revenues of $65 million, a 42% increase from 2022. Key achievements included the acquisition of CellerateRX assets and the launch of new medical products. However, the company also reported a loss before income taxes of $4.4 million, alongside increased expenses in SG&A and R&D. CEO Fleming expressed optimism about continued growth and strategic advancements in 2024.
Read more →SMTIThe Good, the Bad, and the Ugly… Aspects of Inflammation
The article discusses the dual nature of inflammation in the immune response. While it is essential for healing and defense against pathogens, excessive inflammation can lead to tissue damage and autoimmune diseases. Understanding these processes is vital for clinicians to promote effective healing and immune function.
Read more →SMTISanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates
Sanara MedTech Inc. has announced the release dates for its fourth quarter and full year earnings for 2023. The earnings release will be issued on March 25, 2024, followed by a conference call on March 26, 2024. This move reflects the company's commitment to transparency and communication with investors as it continues to focus on developing innovative medical technologies.
Read more →SMTIEvaluation of Microbicidal Efficacy of BIASURGE® Advanced Surgical Solution
This study evaluates the microbicidal efficacy of BIASURGE Advanced Surgical Solution against 18 microorganisms over 24 hours. It also includes a 28-day preservative challenge as per USP <51>. The findings indicate strong efficacy, with detailed methodology and implications discussed.
Read more →SMTISanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023 FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. has announced its unaudited preliminary results for the fourth quarter and full-year 2023, indicating strong sales growth within its product lines, particularly CellerateRX Surgical and its advanced biologics portfolio. Despite positive outcomes, the company acknowledged that the final financial figures may differ from these preliminary results due to audits and other potential developments. The company remains focused on improving clinical outcomes and reducing healthcare costs in the surgical and wound care sectors.
Read more →SMTITechnological Advances in Next-Generation Bone Grafts
The article discusses the evolution of bone graft technologies, focusing on synthetic, allograft, and cellular bone grafts. It highlights advancements in next-generation osteoinductive DBMs and the benefits of using proprietary cryopreservatives for cellular grafts. The risks associated with DMSO in cellular grafts are also addressed, emphasizing the importance of selecting appropriate graft materials based on clinical needs.
Read more →SMTI▼ -5.1%on this news
Sanara MedTech Inc. Announces Exclusive License Agreement for Patented Collagen Peptides
Sanara MedTech Inc. has entered into an exclusive licensing agreement with Tufts University to develop and commercialize patented technologies for 18 unique collagen peptides. This agreement is expected to expand Sanara's existing product line and enable new applications that could improve patient care and reduce healthcare costs. As part of the agreement, Sanara has established a new subsidiary, Sanara Collagen Peptides, LLC, which will have exclusive rights to develop and market products based on the licensed technologies. The deal includes structured royalty payments to Tufts based on product sales.
Read more →SMTI▲ +7%on this news
Matrix-Derived Peptides Orchestrate a Wound Healing Symphony
The article discusses the critical roles of matrix-derived peptides in surgical wound healing, likening the process to a well-orchestrated performance. These peptides facilitate cell migration, modulate inflammation, regulate angiogenesis, and enhance extracellular matrix remodeling, all vital for effective tissue repair. The advancement of peptide-based therapeutics and scaffolds is highlighted as a promising avenue for improving wound healing outcomes.
Read more →SMTISanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX Surgical Powder) Was Used to Promote Wound Healing
Sanara MedTech Inc. announced the publication of a study indicating that its CellerateRX Surgical Powder significantly reduces surgical site infections in patients undergoing elective surgeries. Conducted with 5,335 patients, the study revealed a 59% decrease in infection rates among those treated with the activated collagen product. This finding supports the company's commitment to enhancing patient outcomes and reducing healthcare costs across various surgical fields. The results suggest the potential for widespread application of CellerateRX in elective surgeries, further validating its previous studies.
Read more →SMTIComparing Delivery Methods of Surgical Wound Irrigation
The article discusses the role of surgical wound irrigation in preventing surgical site infections (SSI). It highlights various delivery methods, including gravity and pulsed irrigation, and their effectiveness. While there is no consensus on the best technique, the choice of method and solution is determined by the surgeon based on specific patient needs. The article emphasizes the importance of irrigation in reducing infection risk.
Read more →SMTISanara MedTech Inc. Announces Third Quarter 2023 Results FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. (SMTI) reported its third-quarter results for 2023, highlighting a record net revenue of $16.0 million and a reduction in net loss to $1.1 million. The company achieved a positive Adjusted EBITDA of $0.3 million and expanded its product offerings through the acquisition of collagen-related assets. New product launches, including ALLOCYTE Plus and BIASURGE, occurred after the quarter ended, contributing to future growth potential. Despite these positives, the growth rate of sales has slowed due to some market challenges and supply issues with certain products.
Read more →SMTISanara MedTech Announces First Sale of ALLOCYTE Plus Advanced Viable Bone Matrix and Provides Other Product Updates
Sanara MedTech Inc. has announced the first sale of its ALLOCYTE Plus Advanced Viable Bone Matrix, a product developed to address previous supply issues with its ALLOCYTE line. The company has ensured adequate supply by partnering with an alternative supplier for in-house processing. Furthermore, the commercial launch of another product, BIASURGE, is anticipated for November 2023, aimed at enhancing surgical procedures. CEO Zach Fleming expressed optimism about these developments positively impacting sales and diversifying the product range.
Read more →SMTISanara MedTech to Participate in Two Upcoming Conferences
Sanara MedTech Inc. announced its participation in two upcoming conferences, aimed at increasing the company's visibility and engagement within the medical technology sector. CEO Zach Fleming will present at the MicroCapClub Leadership Summit and the Cantor Fitzgerald Global Healthcare Conference. The presentations will focus on the company's transformative technologies for surgical, wound, and skincare markets, with materials available on their website prior to the events. This participation reflects Sanara's commitment to enhancing its market position and potentially expanding its investment opportunities.
Read more →SMTIEliminating and Preventing Microorganisms in the Operating Room
The article discusses the significant issue of Surgical Site Infections (SSIs) in the U.S., affecting 1 in 31 surgical patients. It highlights the challenges posed by antibiotic-resistant microorganisms and outlines various entry routes for pathogens during surgery. The piece also presents effective strategies for infection prevention, including improved sterilization practices and hand hygiene protocols, which have contributed to a 5% reduction in SSIs over the past five years.
Read more →SMTIWhat to Expect From a Hip or Knee Revision: Understanding the Need, Treatment, and Recovery Process for Patients
The article discusses the necessity and process of hip or knee revision surgeries. It outlines reasons for surgery, including wear and tear, loosening, trauma, infection, and implant failure. The treatment process involves preoperative evaluations, anesthesia, and surgical procedures, followed by a recovery phase that emphasizes rehabilitation and gradual return to activities. Understanding these aspects can help patients approach their surgery with confidence.
Read more →SMTISanara MedTech Inc. Announces Second Quarter 2023 Results FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. has announced its financial results for Q2 2023, reporting a record revenue of $15.8 million, a significant increase from the previous year. The company attributed this growth to higher sales of soft tissue repair and bone fusion products. Additionally, Sanara completed an acquisition of collagen products, which is expected to further improve operational performance and reduce costs by eliminating prior royalty payments. However, the firm also reported a net loss of $1.9 million, influenced by supply issues related to one product, although improvements are anticipated.
Read more →SMTISanara MedTech Inc. Announces the Acquisition of Certain Assets Related to its Collagen Products Business FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. has announced the acquisition of assets related to its collagen products business from Applied Nutritionals, LLC and others. This acquisition includes rights to manufacturing and a portfolio of collagen-based wound care products, which the company believes will enhance their R&D efforts and reduce costs. The deal was valued at $15.25 million, with additional earnout payments based on future sales. This strategic move aims to eliminate royalties and improve Sanara's operational efficiency in the surgical and wound care markets.
Read more →SMTISanara MedTech Inc. Announces First Quarter 2023 Results FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. reported a record revenue quarter for Q1 2023, with March being the highest sales month in the company's history. This growth was attributed to an increasing number of facilities selling their products and an expanded product line. The company also submitted its Precision Healing Multispectral Imager for 510(k) clearance and successfully received 510(k) clearance for its BIASURGE Advanced Surgical Solution, which is set for commercial launch in late 2023. However, the company faced supply issues with the ALLOCYTE product line due to stringent donor screening, affecting certain orders and sales during this period.
Read more →SMTISanara MedTech Inc. Announces 510(k) Clearance for BIASURGE™ Advanced Surgical Solution
Sanara MedTech Inc. has announced that it has received 510(k) clearance for its BIASURGE™ Advanced Surgical Solution. This proprietary technology is intended to improve the mechanical cleansing of wounds by effectively removing debris and microorganisms. The company sees this clearance as a significant step in advancing its product offerings in the surgical market. BIASURGE™ is expected to be commercially available by late 2023, enhancing Sanara's portfolio in wound care and surgical products.
Read more →SMTISanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Results FORT WORTH, TX / GlobeNewswire /
Sanara MedTech Inc. released its financial results for Q4 and full-year 2022, reporting a significant increase in net revenues to $45.8 million, marking a 90% rise from the previous year. The company experienced record sales, driven by the CellerateRX product line and the expansion of its sales team. However, Sanara also faced challenges, with a net loss of $8.1 million due to elevated selling, general, and administrative expenses, as well as increased research and development costs. Future growth is supported by a strategic partnership with InfuSystem and ongoing product development efforts.
Read more →SMTISanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Earnings Release and Conference Call Dates
Sanara MedTech Inc. announced the details of its fourth quarter and full year 2022 earnings release and conference call. The earnings release is scheduled for March 20, 2023, with a conference call following on March 21 at 9:00 a.m. Eastern Time. Stakeholders will have the opportunity to engage with management via the call, which will also be available online. This release shows the company’s commitment to transparency and connection with its investors.
Read more →SMTISanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2022 FORT WORTH, TX / GLOBENEWSWIRE /
Sanara MedTech Inc. has released preliminary unaudited results for Q4 and full year 2022, indicating a substantial increase in net revenue. For Q4, the company reported $15.3 million in revenue, a 119% rise from the previous year, with total annual revenue reaching $45.8 million, up 90%. However, the company also faced increased operating losses due to rising expenses related to acquisitions and R&D. A significant non-cash loss was recorded from the dissolution of Sanara Pulsar, affecting product adoption due to reimbursement issues.
Read more →SMTISanara MedTech to Participate in Two Upcoming Healthcare Conferences
FORT WORTH, TX, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Zach Flem
Read more →SMTISanara MedTech Inc. Announces Third Quarter 2022 Results FORT WORTH, TX / GLOBENEWSWIRE /
MedTech Inc. Announces Third Quarter 2022 Results WORTH, TX / GLOBENEWSWIRE / November 14, 2022 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ: SMTI), a provider of products and technologies for surg
Read more →SMTISanara MedTech and InfuSystem Announce Wound Therapy Partnership
FORT WORTH, TX, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI) and InfuSystem Holdings, Inc. (“InfuSystem”) (NYSE American: INFU) announced today the establishment of a partnership, SI Wound Care, LLC (“SI Wound
Read more →SMTI▲ +9.5%on this newsshared move
Sanara MedTech Inc. Announces Third Quarter 2022 Earnings Release and Conference Call Dates
FORT WORTH, TX, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving
Read more →SMTISanara MedTech to Present at the Virtual MicroCap Leadership Summit
FORT WORTH, TX, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that it has b
Read more →SMTISanara MedTech Inc. Announces Second Quarter 2022 Results FORT WORTH, TX / ACCESSWIRE /
MedTech Inc. Announces Second Quarter 2022 Results WORTH, TX / ACCESSWIRE / August 15, 2022 / Sanara MedTech Inc. in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ: SMTI), a provider of products and technologies for surgical and c
Read more →SMTISanara MedTech Inc. Announces Second Quarter 2022 Earnings Release and Conference Call Dates
FORT WORTH, TX, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for th
Read more →SMTISanara MedTech Inc. Announces Closing of Scendia Biologics, LLC Acquisition FORT WORTH, TX /
MedTech Inc. Announces Closing of Scendia Biologics, LLC Acquisition WORTH, TX / July 5, 2022 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ: SMTI), a provider of products and technologies for surgica
Read more →SMTISanara MedTech Inc. Announces First Quarter 2022 Results FORT WORTH, TX /
Sanara MedTech Inc. Announces First Quarter 2022 Results TX / May 16, 2022 / Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes,
Read more →SMTISanara MedTech Inc. Announces First Quarter 2022 Earnings Release and Conference Call Dates
FORT WORTH, TX, May 02, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for the
Read more →SMTI▲ +8.6%on this news
Sanara MedTech Inc. Announces Entry into Merger Agreement to Acquire Precision Healing Inc. FORT WORTH, TX / GlobeNewswire /
MedTech Inc. Announces Entry into Merger Agreement to Acquire Precision Healing Inc. WORTH, TX / GlobeNewswire / April 4, 2022 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ: SMTI), a provider of prod
Read more →SMTI▲ +8.6%on this news
Sanara MedTech Inc. Announces Closing of Merger to Acquire Precision Healing Inc. FORT WORTH, TX /
MedTech Inc. Announces Closing of Merger to Acquire Precision Healing Inc. WORTH, TX / April 4, 2022 / Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to imp
Read more →SMTISanara MedTech Inc. Announces Fourth Quarter and Full Year 2021 Results FORT WORTH, TX / GlobeNewswire /
MedTech Inc. Announces Fourth Quarter and Full Year 2021 Results WORTH, TX / GlobeNewswire / March 30, 2022 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ: SMTI), a provider of products and technologi
Read more →SMTISanara MedTech Inc. Announces Fourth Quarter and Full Year 2021 Earnings Release and Conference Call Dates
FORT WORTH, TX, March 14, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving
Read more →SMTISanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2021 FORT WORTH, TX /
MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2021 WORTH, TX / February 22, 2022 / Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated t
Read more →SMTISanara MedTech Inc. Announces the Appointment of Zachary B. Fleming as Chief Executive Officer FORT WORTH, TX /
MedTech Inc. Announces the Appointment of Zachary B. Fleming as Chief Executive Officer WORTH, TX / December 28, 2021 / Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to impro
Read more →SMTISanara MedTech Inc. Announces the Retirement of J. Michael Carmena and Appointment of Eric Tanzberger to its Board of Directors FORT WORTH, TX /
MedTech Inc. Announces the Retirement of J. Michael Carmena and Appointment of Eric Tanzberger to its Board of Directors WORTH, TX / December 22, 2021 / Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ: SMTI), a provider of products and technologies for surgical and chro
Read more →SMTISanara MedTech Inc. Announces the Appointment of Roszell Mack III to its Board of Directors FORT WORTH, TX /
MedTech Inc. Announces the Appointment of Roszell Mack III to its Board of Directors WORTH, TX / December 15, 2021 (Globe Newswire) -- Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care ded
Read more →SMTISanara MedTech Inc. Announces Third Quarter 2021 Results and Business Update FORT WORTH, TX / ACCESSWIRE /
PRESS RELEASE ISSUED NOVEMBER 12, 2021 smti_ex991.htm EXHIBIT 99.1 Sanara MedTech Inc. Announces Third Quarter 2021 Results and Business Update FORT WORTH, TX / ACCESSWIRE / November 12, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the
Read more →SMTI▼ -6.9%on this news
Sanara MedTech Inc. Announces Second Quarter 2021 Results and Business Update FORT WORTH, TX / ACCESSWIRE /
smti_ex991.htm EXHIBIT 99.1 Sanara MedTech Inc. Announces Second Quarter 2021 Results and Business Update FORT WORTH, TX / ACCESSWIRE / Aug 16, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ: SM
Read more →SMTISanara MedTech Inc. Announces the Purchase of Certain Assets from Rochal Industries, LLC FORT WORTH, TX / ACCESSWIRE /
Sanara MedTech Inc. Announces the Purchase of Certain Assets from Rochal Industries, LLC FORT WORTH, TX / ACCESSWIRE / July 19, 2021 / Sanara MedTech Based in Fort Worth, Texas, Sanara MedTech Inc. ( Sanara, the Company, we, our or us ) (NASDAQ: SMTI), a provider of surgica
Read more →SMTISanara MedTech Inc. Announces Exclusive Partnership with Pixalere Healthcare Inc. to Advance its Comprehensive Wound and Skin Care Strategy FORT WORTH, TX / ACCESSWIRE /
Sanara MedTech Inc. Announces Exclusive Partnership with Pixalere Healthcare Inc. to Advance its Comprehensive Wound and Skin Care FORT WORTH, TX / ACCESSWIRE / June 4, 2021 / Sanara MedTech Based in Fort Worth, Texas, Sanara MedTech Inc. ( Sanara, the Company, we, our or us
Read more →SMTISanara MedTech Inc. Announces Proposed Public Offering of Common Stock FORT WORTH, TX / ACCESSWIRE /
Sanara MedTech Inc. Announces Proposed Public Offering of Common FORT WORTH, TX / ACCESSWIRE / February 11, 2021 / Sanara Based in Fort Worth, Texas, Sanara MedTech Inc. ( Sanara, the Company, we, our or us ) (NASDAQ: SMTI), a provider of wound and skin care products dedicat
Read more →SMTIsmti_ex991 Sanara MedTech Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2020 FORT WORTH, TX / ACCESSWIRE /
Sanara MedTech Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2020 FORT WORTH, TX / ACCESSWIRE / January 25, 2021 / Sanara Based in Fort Worth, Texas, Sanara MedTech Inc. ( Sanara or the Company ) (NASDAQ: SMTI), a provider of wound and skin care pro
Read more →SMTIADDITIONAL EXHIBITS smti_ex991
ADDITIONAL EXHIBITS smti_ex991
Read more →SMTIsmti_ex991
PRESS RELEASE smti_ex991
Read more →SMTISanara MedTech Inc. Announces the Appointment of Bob DeSutter to Its Board of Directors FORT WORTH, TX / ACCESSWIRE /
MedTech Inc. Announces the Appointment of Bob DeSutter to Its Board FORT WORTH, TX / ACCESSWIRE / October 15, 2020 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara" or the "Company") (OTCQB:SMTI), a provider of wound and skin care products and vi
Read more →SMTISanara MedTech Inc. Announces Closing of $10,000,000 Private Placement of Common Stock FORT WORTH, TX / ACCESSWIRE /
MedTech Inc. Announces Closing of $10,000,000 Private Placement of FORT WORTH, TX / ACCESSWIRE / October 16, 2019 / Sanara MedTech Inc. (OTCQB: SMTI). Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara"), a provider of surgical and chronic wound care products dedicated
Read more →SMTIWound Management Technologies Reports Preliminary Financial Results for the Third Quarter of 2015 ADDISON, TX / ACCESSWIRE /
Wound Management Technologies Reports Preliminary Financial Results for the Third Quarter of 2015 ADDISON, TX / ACCESSWIRE / October 7, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and
Read more →SMTIWound Management Technologies, Inc. Schedules First Quarter 2015 Earnings call for Wednesday
Wound Management Technologies, Inc. Schedules First Quarter 2015 Earnings call for Wednesday, April 22, 2015 Addison, TEXAS, April 20, 2015 - Wound Management Technologies, Inc. (OTC QB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and
Read more →SMTILETTER TO SHAREHOLDERS wmti8kex991053012.htm NEWS BULLETIN From: Wound Management Technologies, Inc. 777 Main Street, Suite 3100 Fort Worth, Texas 76102 For Further Information: Shareholder Relations-Communications (800)
From: Wound Management Technologies, Inc. 777 Main Street, Suite 3100 Fort Worth, Texas 76102 For Further Information: Shareholder Relations-Communications (800) 205-7719 Annual CEO Letter to Wound Management Technologies Shareholders FORT WORTH, Texas, May 29, 2012 PRNewsw
Read more →SMTIPRESENTATION wmti8kex991092711.htm
PRESENTATION wmti8kex991092711.htm
Read more →SMTIPRESENTATION MATERIALS wmti8kex991111110.htm
PRESENTATION MATERIALS wmti8kex991111110.htm
Read more →SMTIPRESENTATION MATERIALS wmit8kex992100610.htm
PRESENTATION MATERIALS wmit8kex992100610.htm
Read more →SMTIPRESENTATION wmti8kex991050610.htm
PRESENTATION wmti8kex991050610.htm
Read more →SMTI: Wound Management Technologies Acquires Resorbable Orthopedics Specialty Medical Products Company Enters $10 Billion Orthopedic Biomaterials Market with Patented Technologies FORT WORTH, TX -
Wound Management Technologies Acquires Resorbable Orthopedics Specialty Medical Products Company Enters $10 Billion Orthopedic Biomaterials Market with Patented Technologies FORT WORTH, TX - Oct.1, 2009 -- Wound Management Technologies, Inc., (OTC BB: WNDM) a rapidly growing p
Read more →SMTINEWS BULLETIN RE: Wound Management Technologies, Inc. 777 Main Street Suite 3100 Fort Worth, Texas 76102 From: Wound Management Technologies, Inc. For Further Information: Product Information Shareholder Re
NEWS BULLETIN RE: Wound Management Technologies, Inc. 777 Main Street Suite 3100 Fort Worth, Texas 76102 From: Wound Management Technologies, Inc. For Further Information: Product Information Shareholder Relations Cathy Bradshaw Lucy Singleton President Secret
Read more →SMTIMBSB Announces Exclusive Worldwide Human Health Care License Rights to its External Wound Care Products FORT WORTH, TX -- (MARKET WIRE) 11/29/07 -- MB Software Corporation (OTCBB: MBSB) announced today that its wholly ow
MBSB Announces Exclusive Worldwide Human Health Care License Rights to its External Wound Care Products FORT WORTH, TX -- (MARKET WIRE) 11/29/07 -- MB Software Corporation (OTCBB: MBSB) announced today that its wholly owned subsidiary Wound Care Innovations LLC has entered in
Read more →Competitive Position
How SMTI ranks across every disease it competes inCompetitive Position is a premium feature
See how SMTI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial